1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Female Sexual Dysfunction - Pipeline Review, H1 2020, provides an overview of the Female Sexual Dysfunction (Women's Health) pipeline landscape.
Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Female Sexual Dysfunction - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Female Sexual Dysfunction (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 3, 7, 1, 1, 5 and 3 respectively.
Female Sexual Dysfunction (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Female Sexual Dysfunction (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Female Sexual Dysfunction (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Female Sexual Dysfunction (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction (Women's Health)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Female Sexual Dysfunction (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Female Sexual Dysfunction (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Female Sexual Dysfunction - Overview
- Female Sexual Dysfunction - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Female Sexual Dysfunction - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Female Sexual Dysfunction - Companies Involved in Therapeutics Development
- Applied Biology Inc
- Better Life Pharmaceuticals Inc
- Callitas Therapeutics Inc
- Can-Fite BioPharma Ltd
- Dare Bioscience Inc
- Emotional Brain BV
- EndoCeutics Inc
- Fabre-Kramer Pharmaceuticals Inc
- H. Lundbeck AS
- Harrow Health Inc
- Ivix Ltd
- Kuhnil Pharmaceutical Co Ltd
- M et P Pharma AG
- Re-Pharm Ltd
- S1 Biopharma Inc
- TherapeuticsMD Inc
- Female Sexual Dysfunction - Drug Profiles
- Product Description
- Mechanism Of Action
- R&D Progress
- Product Description
- Mechanism Of Action
- R&D Progress
- AB-101 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BP-101 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- estradiol - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- FKW-00GA - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Female Sexual Dysfunction - Dormant Projects
- Female Sexual Dysfunction - Discontinued Products
- Female Sexual Dysfunction - Product Development Milestones
- Featured News & Press Releases
- Mar 09, 2020: Dare Bioscience presents positive Sildenafil Cream, 3.6% data supporting further development for the treatment of female sexual arousal disorder
- Dec 11, 2019: Daré Bioscience announces alignment with the FDA on phase 2b study design and novel primary endpoint PRO instruments to support the continued clinical development of Sildenafil Cream, 3.6%, a potential therapy for Female Sexual Arousal Disorder
- Oct 30, 2019: Knight and TherapeuticsMD announce filing of new drug submission for Joyesta in Canada
- Oct 28, 2019: Dare Bioscience and Strategic Science & Technologies announce presentation of positive findings from thermography clinical study of Sildenafil Cream, 3.6 % in healthy women at the Sexual Medicine Society of North America Conference
- Oct 08, 2019: Mayfield Pharmaceuticals to Present update on lidocaine at the SVB Leerink New Treatments Focused on Women’s Health Conference on October 10, 2019
- Sep 24, 2019: TherapeuticsMD announces multiple presentations related to IMVEXXY at the 2019 Annual Meeting of the North American Menopause Society
- Sep 12, 2019: Ovoca announces filing of marketing authorisation application with Russian Ministry of Health for BP-101
- Jun 17, 2019: Daré Bioscience announces positive results in Thermography feasibility study with Sildenafil Cream, 3.6%, a potential therapy for female sexual arousal disorder
- Apr 23, 2019: Ovoca Bio announced US and EU clinical development plans
- Mar 25, 2019: Ovoca Bio Libicore (BP-101) meets primary/secondary endpoints in phase 3 trial for hypoactive sexual desire disorder ahead of time
- Mar 18, 2019: Dare Bioscience to present update on Sildenafil Cream at 31st Annual ROTH Conference
- Jan 04, 2019: S1 Biopharma announces expanded analysis of phase 2a data on Lorexys for treatment of hypoactive sexual desire disorder based on PGIC scale to be presented at 2019 ISSWSH/ISSM joint meeting
- Dec 20, 2018: S1 Biopharma granted patents for Lorexys in Europe and Asia for treatment of hypoactive sexual desire disorder
- Nov 29, 2018: Dare Bioscience announces initiation of content validity study for Sildenafil Cream, 3.6%, a potential therapy for female sexual arousal disorder
- Nov 27, 2018: Dare Bioscience Announces Enrollment in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact
- Disclaimer
List of Tables
- Number of Products under Development for Female Sexual Dysfunction, H1 2020
- Number of Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Female Sexual Dysfunction - Pipeline by Applied Biology Inc, H1 2020
- Female Sexual Dysfunction - Pipeline by Better Life Pharmaceuticals Inc, H1 2020
- Female Sexual Dysfunction - Pipeline by Callitas Therapeutics Inc, H1 2020
- Female Sexual Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H1 2020
- Female Sexual Dysfunction - Pipeline by Dare Bioscience Inc, H1 2020
- Female Sexual Dysfunction - Pipeline by Emotional Brain BV, H1 2020
- Female Sexual Dysfunction - Pipeline by EndoCeutics Inc, H1 2020
- Female Sexual Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2020
- Female Sexual Dysfunction - Pipeline by H. Lundbeck AS, H1 2020
- Female Sexual Dysfunction - Pipeline by Harrow Health Inc, H1 2020
- Female Sexual Dysfunction - Pipeline by Ivix Ltd, H1 2020
- Female Sexual Dysfunction - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2020
- Female Sexual Dysfunction - Pipeline by M et P Pharma AG, H1 2020
- Female Sexual Dysfunction - Pipeline by Re-Pharm Ltd, H1 2020
- Female Sexual Dysfunction - Pipeline by S1 Biopharma Inc, H1 2020
- Female Sexual Dysfunction - Pipeline by TherapeuticsMD Inc, H1 2020
- Female Sexual Dysfunction - Dormant Projects, H1 2020
- Female Sexual Dysfunction - Dormant Projects, H1 2020 (Contd..1), H1 2020
- Female Sexual Dysfunction - Discontinued Products, H1 2020
List of Figures
- Number of Products under Development for Female Sexual Dysfunction, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Applied Biology Inc
- Better Life Pharmaceuticals Inc
- Callitas Therapeutics Inc
- Can-Fite BioPharma Ltd
- Dare Bioscience Inc
- Emotional Brain BV
- EndoCeutics Inc
- Fabre-Kramer Pharmaceuticals Inc
- H. Lundbeck AS
- Harrow Health Inc
- Ivix Ltd
- Kuhnil Pharmaceutical Co Ltd
- M et P Pharma AG
- Re-Pharm Ltd
- S1 Biopharma Inc
- TherapeuticsMD Inc
